|Bid||104.91 x 1000|
|Ask||105.00 x 1200|
|Day's Range||104.62 - 106.87|
|52 Week Range||82.12 - 121.98|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||44.13|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
A Raleigh-based clinical research organization plans a stock buyback worth half a billion dollars as its largest institutional shareholder plans to sell its stake.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
A Triangle-based contract research organization says Asian-Pacific markets present a massive opportunity for expansion, potentially adding to its already double-digit growth.
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 1.67% and -0.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It hasn't been the best quarter for PRA Health Sciences, Inc. (NASDAQ:PRAH) shareholders, since the share price has...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
PRA Health Sciences Inc NASDAQ/NGS:PRAHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for PRAH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PRAH. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PRAH totaled $150 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 3.77% and -1.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Raleigh, North Carolina-based company said it had profit of 66 cents per share. Earnings, adjusted for amortization costs and stock option expense, came to $1.10 per share. The results surpassed Wall ...